For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Semaglutide
Weight & Metabolicapproved

Semaglutide

Ozempic
Weight & Metabolic · CAS 910463-68-2
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
A
PubMed records
5,189
Female-tagged
1,116
Sex-analysis
14
CAS
910463-68-2
A
Evidence grade A, Approved indication with 1116 indexed studies that included female subjects. How grades work →
Female evidence: Direct
Semaglutide: of 5,189 PubMed records, 1,116 are tagged as including female subjects and 14 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Semaglutide is a long-acting GLP-1 receptor agonist and one of the most extensively characterized compounds in metabolic research. It is an approved medicine for type 2 diabetes and chronic weight management, and its large clinical program has made it a well-defined reference point among incretin-based agents.

Semaglutide has been studied for its GLP-1 receptor agonism, through which it enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central signaling pathways. It has been investigated across diabetes, obesity, and broader cardiometabolic research models, making it a frequent comparator for newer single- and multi-agonist compounds.

What makes semaglutide notable for a weight, metabolic, and hormonal-reproductive catalog is the depth of its characterization relative to most peptides in this space. Questions such as how cycle phase and contraceptive absorption interact with its pharmacology remain only partially answered; our evidence review tracks how many of the underlying studies included women.

Summary

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with large trials that enrolled substantial numbers of women. It is one of the best-studied compounds here in female subjects, though cycle-phase and contraceptive-absorption questions remain only partially answered.

Evidence in women

Menstrual cycle
Unstudied
Appetite and nausea effects have not been systematically evaluated across menstrual cycle phases.
Pregnancy & lactation
Contraindicated
Contraindicated in pregnancy; discontinue at least 2 months before a planned pregnancy per label. Not established in lactation.
Hormonal interactions
Evidence
Delayed gastric emptying can affect oral drug absorption; the oral formulation carries specific timing guidance relevant to oral contraceptive users.
Perimenopause & menopause
No evidence
No dedicated trials in perimenopausal weight change; broad female enrollment includes this age range but outcomes are not stratified by menopausal status.
Sex differences
Evidence
In the indexed literature, many studies included women, but only reported sex-stratified efficacy or safety outcomes.

Mechanism

Long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central pathways.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Per approved label; titrated. Reported here for reference, not as advice.
Routessubcutaneous, oral
Female-specific dosingNot established

Contraindications: personal/family history of medullary thyroid carcinoma; MEN 2; pregnancy

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrheadelayed gastric emptying

Semaglutide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Semaglutide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Semaglutide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Semaglutide?

Semaglutide, also known as Ozempic, is a research compound in our weight metabolic category. Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with large trials that enrolled substantial numbers of women.

Is Semaglutide studied in women?

Semaglutide: of 5,189 PubMed records, 1,116 are tagged as including female subjects and 14 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.

Has Semaglutide been studied during pregnancy or breastfeeding?

Contraindicated. Contraindicated in pregnancy; discontinue at least 2 months before a planned pregnancy per label. Not established in lactation. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Semaglutide have, and why?

Semaglutide carries evidence grade A. Approved indication with 1116 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Semaglutide?

No. A female-specific dose for Semaglutide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Semaglutide administered in research?

In the published literature, Semaglutide is administered via subcutaneous, oral. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Semaglutide?

Effects reported in the research literature include nausea, vomiting, diarrhea, delayed gastric emptying. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Semaglutide?

The CAS registry number for Semaglutide is 910463-68-2. It is also referred to as Ozempic, Wegovy, Rybelsus. Use it to confirm identity against a Certificate of Analysis.

How should Semaglutide be stored and handled?

Semaglutide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Semaglutide for research?

For laboratory research use, Semaglutide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Semaglutide at Aurevena Research
Research-use supplier: Semaglutide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

33567185 · 34499544

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.